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Potential Biomarkers of thyroid neoplasia: the impact of 
proteomics analysis in the diagnosis. 
 
Summary 
Fine-needle aspiration cytology (FNA) is the most important tool to correctly 
address a thyroid lesion. Thyroid cancers account for about 5% of all lesions. 
A correct diagnosis may be difficult using FNA. Thyroid biomarkers help to 
better characterized thyroid lesions. Among the new techniques, proteomics , 
since 2002, has been increasingly used. In this thesis we describe the results 
obtained by the proteomic analysis of thyroid FNA to detect potential 
biomarkers for thyroid neoplasia and its impact in clinical management of 
thyroid malignancies. 
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INTRODUCTION 
The most important diagnostic approach to distinguish between benign and 
malignant thyroid nodules is represented by fine-needle aspiration cytology 
(FNA)
1,2
. Malignant thyroid tumors account for about 5% of all thyroid 
lesions
3,4
. A correct diagnosis of FNA samples may sometimes be difficult 
using the traditional tools
5-6
. Recently, the discovery of thyroid biomarkers 
has led to the identification of various proteins which help to better 
characterized thyroid lesions
6-8
. Among the new techniques, since 2002, 
proteomics has been used to differentiate thyroid malignancies from benign 
lesions
9-14
. The aim of this thesis is to describe the results obtained by the 
proteomic analysis of thyroid FNA to detect potential biomarkers for thyroid 
neoplasia and its impact in clinical management of thyroid malignancies. 
PATIENT AND METHODS 
Chemicals 
Iodoacetamide (IAA), CHAPS, urea, thiourea, glycerol, SDS, TEMED, 
ammonium persulfate, glycine, 30% acrylamide-N,N,N-bisacrylamide, 
trifluoroacetic acid (TFA), HEPES and copper sulphate were acquired from 
Sigma-Aldrich (St. Louis, MO, USA). Sodium chloride (NaCl), acetonitrile 
(ACN) from J.T. Baker. Sodium acetate, Trizma base, SDS, DTT and 
trichloroacetic acid (TCA) from AppliChem. IPGs pH 3–10 NL, pharmalyte 
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3–10 NL and dry strip cover fluid were purchased from GE Health Care, 
Europe (Uppsala, Sweden). Coomassie Brilliant Blue G 250 was from Merck 
(Darmstadt, Germany). All other reagents were supplied by standard 
commercial sources and were of the highest grade available. 
Patients 
The study was conducted between October 2005 and April 2010. A full 
clinical evaluation and routine laboratory tests were performed and all 
patients. Inclusion criteria were represented by normal preoperative values of 
free F-T3, F-T4 and thyroid stimulating hormone (TSH). Detectable serum 
anti-thyroid peroxidase (Ab-TPO) and anti-thyroglobulin antibodies (Ab-Tg) 
were considered exclusion criteria to dismiss patients from the study. Therapy 
with L-thyroxine at the time of the surgery was also considered as an 
exclusion criterion. An informed consensus was obtained from all patients for 
diagnostic or clinical purposes. The study was approved by the local Ethics 
Committee. The normal and malignant nature of FNA samples was assessed 
by histological analysis
6
. Formalin-fixed and paraffin-embedded samples of 
thyroid tissues were stained by hematoxylin and eosin (E&E). Definitive 
diagnoses of benign lesion or  thyroid carcinoma were performed in 
accordance with the guidelines of the World Health Organization (WHO)
 3
. 
Seventy-seven patients were enrolled in the study. There were 15 males and 
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62 female patients. Mean age (years, ±SD) was 47.2 ±14.0 years (range 22-
75). A surgical procedure of total thyroidectomy was achieved in all patients.
 
Sample collection and preparation 
Immediately after surgical removal of the thyroid, a FNA with a 23G needle 
was performed by the surgeon on the suspected nodule. The same procedure 
was performed in the normal tissue (control sample) of the opposite lobe. 
After passing the needle through the tissue 3 or 4 times, 4 mL of saline 
solution were aspirated with the same syringe. This fluid collected was 
immediately centrifuged at 2300g for 20 min at 4 °C and processed. Proteins 
from resulting supernatants were precipitated using 10% (w/v) trichloroacetic 
acid (TCA) and 0.05% ditiothreitol (DTT). After incubation at 0 °C for 1 h, 
the insoluble material was pelleted at 14000g. The pellets were washed three 
times with pure acetone, air-dried and solubilized in 7 M urea, 2 M thiourea, 
4% CHAPS, 60 mM DTT, 0.5% 3-10 ampholytes and 0.002% bromophenol 
blue (rehydration solution). The amount of protein was estimated by means of 
a RC DC protein assay from Bio-Rad. The protein amount was determined 
using Bio-Rad RC DC-protein assay. Bovine serum albumin (BSA) was used 
as a standard. 
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2-DE analysis 
For analytical gels, 150 μg of proteins, for each sample, were filled up to 350 
μl in 7M urea, 2M thiourea, 4% CHAPS, 60mM DTT, 0.5% 3-10 ampholytes 
and 0.002% bromophenol blue (rehydration solution). Isoelectrofocusing 
(IEF) was carried out by using 18 cm Immobiline Dry-Strips (GE Healthcare) 
with a non linear, pH 3-10, gradient. IEF was performed at 16°C on an Ettan 
IPGphor II apparatus (Amersham Biosciences), according to the following 
schedule: the samples were applied by in-gel rehydration for 10 h using low 
voltage (30 V), then the voltage was linearly increased from 200 to 5000 
during the first 4 h, and then the proteins were focused for up to 70 000Vh at 
a maximum voltage of 8000 V. To prepare the IPG strips for the second 
dimension, the strips were first equilibrated 15 min at room temperature in a 
buffer containing 50 mM Tris-HCl, pH 8.8, 6 M Urea, 30% glycerol, 2% 
SDS, 0.002% bromophenol blue, 1% DTT, followed by a second 
equilibration for 10 min in the same buffer except that DTT was replaced by 
2.5% IAA. Subsequently, the IPG strips were applied horizontally on top of 
12.5% SDS-polyacrylamide gels (20x18x0.15 cm) and electrophoresis was 
performed using the PROTEAN-II Multi Cell system (Bio-Rad) with constant 
amperage (40mA/gel) at 10 °C until the dye front reached the bottom of the 
gel (about 5 h) applying a continuous buffer system. 
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Staining and image analysis 
The analytical gels were stained with ammoniacal silver nitrate. The 
procedure of silver staining consisted of five sequential phases including 
protein fixation, sensitization, silver impregnation, image development and 
stopping. To ensure that the spot staining was within the values of the 
linearity range, the silver stain was performed in standard conditions of time 
and temperature. All solutions were kept at 4°C, except for silver solution, 
while room temperature was controlled at 18°C. All steps were performed on 
an orbital shaker. Briefly, at the end of the second dimension run, the gels 
were removed from the glass plates, washed in deionized water for 5 min, 
soaked in ethanol: acetic acid: water (40: 10: 50) for 1 hour and then soaked 
in ethanol: acetic acid: water (5: 5: 90) overnight. After protein fixation, the 
gels were washed in deionized water for 5 min at 4°C and soaked in a solution 
containing glutaraldehyde (1%) and sodium acetate (0.5 M) for 30 min. After 
washing 3 times in deionized water for 10 min at 4°C, the gels were soaked 
twice in a 2.7 naphtalene-disulfonic acid solution (0.05% w/v) for 30 min at 4 
°C in order to obtain homogeneous dark brown staining of the proteins. Then 
the gels were rinsed 4 times in deionized water for 15 min at 4 °C. Staining 
was carried out in a freshly made ammoniacal (30%) silver nitrate (2.5%) 
solution for 30 minutes at 18 °C. After staining, the gels were washed 4 times 
in deionized water for 4 min at 4°C. The images were developed in a solution 
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containing citric acid (0.01% w/v) and formaldehyde (0.1% v/v) for 5 
minutes. Development was stopped with a solution containing Tris (0.4M) 
and acetic acid (2% v/v). The stained gels were scanned using an Epson 
Expression 1680 Pro scanner and the images were analyzed using Image-
Master 2D Platinum 6.01 (GE Health Care Europe, Uppsala). Spots were 
automatically detected, manually edited and then counted. After spot 
detection in gels, a match set and a synthetic image for each class was 
generated. A synthetic gel was obtained by averaging the positions, shapes, 
and optical densities of the matched spots in the set of gels class. This 
produces an intersection of all the gels, showing only the spots found in 
almost 75% of the images of each class. 
Statistical analysis 
The optical density of the proteins was expressed as a percentage of the 
volume, (mean ± SD) of the spots representing a certain protein that was 
determined in comparison with the total number of proteins present in the 2-
DE gel. The significance of the differences (p value <0.05) was calculated 
using Mann-Whitney test. 
Preparative gels 
In order to identify proteins of interest, preparative gels are performed and 
stained with Coomassie Brilliant Blue G-colloidal. This detection method is 
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compatible with mass spectrometry but less sensitive than silver staining 
therefore, for preparative gels, we had to load 1500 μg of proteins. For first 
dimension, a preliminary step at 200 V for 12 h was introduced, while second 
dimension is the same as analytical gels. The preparative gels for mass 
spectrometric analysis were stained with Coomassie Brilliant Blue G-colloidal 
(0,12%Coomassie G-250, 10% ammonium sulfate, 2% phosphoric acid). 
Briefly, after protein fixation with acetic acid (7%) and methanol (40%) for 1 
h, the gels were stained overnight with Coomassie Brilliant Blue G-colloidal 
diluted with methanol (4:1 v/v). The gels were then rinsed 60 seconds with a 
solution of acetic acid (10%) and methanol (25%) and finally washed twice 
for few seconds with a solution of methanol (25%). Both analytical and 
preparative gels showed the same protein pattern. Protein spots of interest 
were cut from gel and sent to Core Facility Proteomic (Université de Genève) 
for analysis by mass spectrometry and protein identification. 
RESULTS  
The first part of our experience was oriented in defining the proteomic profile 
of human thyroid FNA fluid. 2DE analysis was performed 17 patients (Ratio 
M:F 6:11, mean age (SD) 48.6(±14.0) years, range 22-75), 2DE analysis with 
silver staining allowed us to recognize about 220 protein’s spot per sample 
(Fig. 1). Therefore a MALDI-TOF peptide mass fingerprint analysis was 
performed on 46 of these spots, identifying 30 different proteins. These latter 
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were classified by function (metabolic, antioxidative, pro-apoptotic, motility, 
other) or usual site (serum proteins). In some cases the same peptide was 
yielded by different spots, suggesting a post-transaltional modification. Table 
1 summarize the proteins identified. Validation of findings was performed by 
means of Western Blot analysis for one protein of each class (Fig 2)
14
.  
Once obtained the proteome of human thyroid FNA, we performed a second 
trial comparing the proteomic analysis on all of the 77 patients (M:F 15:62, 
mean age 47.2±14.0 years, range 22-75) which had a preoperative diagnosis 
either suspicious or highly suggestive of a thyroid carcinoma (FNA Bethesda 
4-6)
3,6
. Final diagnosis, as represented in (Table 2), was of classical variant of 
papillary carcinoma (cPTC) in 25 patients, follicular variant (PFV) in 15, tall 
cells variant (TCV) in 12, benign follicular lesion in 21. In the other 4 patients 
were found: 2 anaplastic thyroid carcinoma (ATC), 1 parathyroid carcinoma 
and 1 Riedel’s thyroiditis. The latter was submitted to surgery for the 
suspicion of an anaplastic thyroid carcinoma. TCV patients showed 
extracapsular involvement in 50% of cases, thus confirming the higher 
aggressiveness of this variant. The proteomic profile on 2DE gel allowed 
finding qualitative and quantitative differences which characterized each 
variant of thyroid cancer from the control tissue. About 200-270 spots were 
identified (Fig.3a-3d). Peptide mass fingerprinting via MALDI-TOF mass 
spectrometry as well as Western Blot analysis were performed to quantify the 
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different expressions of each detected proteic spots respect to control tissue in 
cPTC and TCV.  Detailed results are showed in Table 3. An up-regulation of 
9 spots was found both ic cPTC and TCV. Between the two sub-type of 
cancer cPTC showed up-regulation of four more proteins: sorting nexin-5, 
moesin, galectin-3 and TTR precursor-spot 63, while in TCV 3 spots were 
exclusively up-regulated: TTR precursor-spot 56, beta actin, serum albumin. 
Moreover each subtype exclusively expressed some protein spots on 2DE gel: 
twelve spots in cPTC and three in TCV (circled spots in Fig.3a, 3b). A 
detailed comparison with cPTC, TCV and normal tissue helped to better 
clarify the up-regulation observed for each spot (Fig.4A-C). 
The proteins profile of FNA of FVC well overlapped with those obtained 
from previous other variants of papillary cancer. Similar to PTC and TCV a 
significant up-regulation of specific functional proteins as glycolitic enzymes, 
serum and structural proteins was oserved when compared to control tissue. 
Specifically was found an increase of ferritin light chain (FLC)(p=0.029), 
protein DJ-1 (p=0.0475) and cofilin-1 (p=0.0021) confirming the potential 
role of these proteins in thyroid cancer progression (Fig.3c).   
The patient in whom a Riedel’s thyroiditis (RT) was diagnosed by final 
histology was a 72-years old woman admitted for a clinical and ultrasound 
findings suspicion of ATC (Fig.5). The 2DE gel was compared to those of an 
ATC (Fig.6). Three proteins which were found to be up-regulated in thyroid 
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cancer (ferritin heavy chain (FHC), FLC, and haptoglobin) were evaluated. 
Protein expression in Riedel’s patients and control tissue did not show 
significative differencies (p= 0.37, 0.73, 0.11 respectively for haptoglobin, 
FLC and FHC), while in ATC expression of haptoglobin, FLC and FHC 
respect RT was significantly increased (p=0.037, 0.035 and 0.047 
respectively). 
DISCUSSION 
Proteomic analysis allowed us to define the human thyroid proteome, 
providing moreover an imaging patter specific for thyroid normal tissue
14
. 
Starting from this pattern we compared FNA samples of sub-type of thyroid 
carcinoma to define the eventual changing presented in protein expression
15
. 
An up-regulation of nine proteins specific protein in all papillary carcinomas 
and moreover four and three proteins exclusively expressed by cPTC and 
TCV respectively was found.   
Analyzing the pattern of proteins hyper-expression our study confirmed the 
earlier findings by Brown and Torres Cabala regarding the upregulation for 
moesin, annexin A1 and gal-3 as well as for FLC, DJ-1 and TTR already 
described for cold nodule or thyroid cancer
9,11-13,15
. Particularly high levels of 
annexin A1 were reported by Petrella comparing well-differentiated and non-
differentiated thyroid cancers, suggesting the role of this protein as a tumor 
suppressor gene, correlating with the degree of tumor differentiation
16
. The 
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role of annexin family seems to be confirmed also by the recent report of Jung 
in which the degree of downregulation of annexin A3 expression (sub-type of 
the group of annexins) correlates with tumor progression in papillary thyroid 
carcinoma
17
.   
Proteomics analysis allowed us to detect in all of the sub-types of cancer 
evaluated an up-regulation of structural protein respect to control. All the 
three variant (cPTC, TCV, FCV) presented significant increased expression of 
Cofilin (p=0.018, p=0.012, p=0.0021, respectively) respect to control
15
. 
Cofilin regulates actin polymerization and depolymerization during cell 
migration, thus directly affecting tumor invasion, thus its different expression 
within the sub-types might indicate a different degree of aggressiveness
15,18
.  
In cPTC exclusively S100A13 up-regulation was found. The S100 protein 
family is a Ca2+ binding protein superfamily, with  25 different peptides 
found in humans so far
19
. S100A13 is involved in non-classical pathway 
transmembrane transport of fibroblast growth factor-1 (FGF-1) and 
interleukin-1a, which are involved in angiogenesis, tumor growth, and cell 
proliferation and differentiation
19
. Specifically, S100A13 acts in the non-
classical (non-vesicular) release of FGF-1 
19,20
. FGF-1, is a potent mitogen 
and angiogenic protein as a participant in the initiation, development and 
metastasis of tumors
19,20
. The importance of S100 family in tumor progression 
has been widely described by different reports in tumorigenesis and thyroid 
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cancer aggressiveness
11,21-24
. Brown determined by immunohistochemistry the 
hyper-expression of S100-A6 in thyroid malignancies
11
, while Sofiadis 
recently reported its up-regulation in papillary thyroid cancer (especially in 
those with a history of previous irradiation) but not in follicular thyroid 
cancer
22
. Moreover Nipp found a correlation in between the expression of 
S100-A10 and S100-A6 and the lymph node metastasis in patients affected by 
papillary carcinoma. So far S100A13 overexpression may be considered, in 
the pattern of S100 family’s actions, as a key factor for cell proliferation and 
tumor progression in cPTC.  
A significant up-regulation of 6-fold to respect with controls was also found 
exclusively in cPTC regarding gal-3, confirming the role of this glycoprotein 
as a biomarker for thyroid carcinoma, as already stated by other 
authors
11,12,25,26
.   
The TTR precursor presented two spot (marked 56 and 63) but each spot was 
more expressed in only one of the two variants. The two spots showed a 
different molecular weight (respectively of 13 and of 34 KDa); the two 
different forms are respectively a monomeric TTR (spot 56) and a oligomeric 
TTR (spot 63). TTR-56 corresponded to a monomeric form typical of TCV, 
while TTR-63, is an oligomeric form due to strong non-covalent interaction 
between monomers, displayed in cPTC
15-17
. The expression of one of the two 
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forms might be related to the different oxidative status or protease activity in 
the specific cancer subtype
15
.   
Focusing on TCV three proteins were exclusively over-expressed FHC, 
peroxiredoxin-1 (PRX1) and 6-phosphogluconate dehydrogenase (6-GHPD). 
FHC showed an increase of 711-fold. It is well known that FHC plays a key 
role in protecting cells from oxidative stress
27
. Thus the level of over-
expression of this protein may correlate with tumor progression and being a 
useful marker for TCV
15
. On the other hand PRX1 itself may concur to the 
effects of FHC, because of its role against oxidative stress, inducing an 
antiapoptotic effect, resulting in abnormal cell proliferation. 6GHPD is one of 
the regulatory factors in the redox pentose phosphate pathway. Hence its role 
may be linked to FHC and PRX1 to provide protection to neoplastic cells 
during tumor proliferation
15
. 
Regarding the patient with RT, a pre-operative work-up was inconclusive for 
a diagnosis and clinical exam suspected an anaplastic carcinoma. Proteomics 
of patient’s samples demonstareted an expression of haptogloblin, FLC, and 
FHC comparable to the FNA of normal thyroid tissues, while in the AC 2DE 
an overexpression of  > 100, > 500 and > 300 was found respectively
28
.  
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CONCLUSIONS 
Our study demonstrated that proteomics may have a preminent role in 
differentiation the profile of thyroid nodules. A specific proteome profile has 
been found for many sub-types of well differentiated (cPTC, TCV, FCV)  and 
anaplastic thyroid carcinoma (ATC) allowing to recognize those forms 
harbouring a clinical higher aggressiveness compared to cPTC, but for which 
usually diagnosis is made only with pathological examination. Although not 
already included in the common clinical practice, the introduction of 
proteomic study on thyroid FNA might help the surgeon to tailor the proper 
care on the patient. 
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FIGURES. 
Fig.1. Results of 2DE (220 spots). 
 
Fig.2. Validation of findings was performed by means of Western Blot 
analysis for one protein of each class. 
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Fig. 3a-3d. 2DE pattern for cPTC, TCV, FVC and AP. 
Fig. 3a. Papillary carcinoma classical variant (cPTC).    
 
Fig. 3b. Papillary carcinoma tall cell variant (TCV). 
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Fig. 3c. Papillary carcinoma. Follicular variant. 
 
Fig. 3d. Anaplastic thyroid carcinoma (ATC). 
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ig. 4. Detailed comparison between normal thyroid tissue (A), cPTC (B) 
and TCV (C), highlighting 2DE findings.  
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fig. 5. US findings in RT patients. 
 
Fig. 6. 2DE comparing of RT(A), ATC(C) and normal thyroid tissue 
(B,D). 
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TABLES. 
Table 1. Human proteomic profile in FNA fluid. 
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Table 2. Final diagnosis on pathological report. 
 
Diagnosis 
 
Number of Patients (n=77) 
 
Papillary carcinoma classical variant (cPTC) 
 
25 
 
Papillary carcinoma follicular variant (PFV) 
 
15 
 
Papillary carcinoma tall cell variant (TCV) 
 
12 
 
Benign lesion 
 
21 
 
Anaplastic  thyroid carcinoma (ATC) 
 
4 
 
Riedel’s Thyroditis 
 
1 
 
Parathyroid carcinoma 
 
1 
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Table 3. Differences between cPTC and TCV on proteins expression. 
 
 
 
 
 
 
 
 
